Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M, Miyake H, Takagi H, Kato T, Terabe K, Wanatabe T, Tsuchiya H, Kida D, Shioura T, Funahashi K, Kato D, Matsubara H, Takahashi N, Hattori Y, Asai N, Ishiguro N. Kojima T, et al. Among authors: hattori y. Mod Rheumatol. 2013 Sep;23(5):977-85. doi: 10.1007/s10165-012-0782-y. Epub 2012 Oct 26. Mod Rheumatol. 2013. PMID: 23099471
Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients.
Takahashi N, Kojima T, Terabe K, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Ishikawa H, Hayashi M, Tsuboi S, Kato D, Funahashi K, Matsubara H, Hattori Y, Hanabayashi M, Hirabara S, Yoshioka Y, Ishiguro N. Takahashi N, et al. Among authors: hattori y. Mod Rheumatol. 2013 Sep;23(5):904-12. doi: 10.1007/s10165-012-0760-4. Epub 2012 Sep 14. Mod Rheumatol. 2013. PMID: 22975734
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity.
Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Ishikawa H, Hayashi M, Tsuboi S, Kanayama Y, Kato D, Funahashi K, Matsubara H, Hattori Y, Hanabayashi M, Hirabara S, Terabe K, Yoshioka Y, Ishiguro N. Takahashi N, et al. Among authors: hattori y. Clin Rheumatol. 2014 Jan;33(1):39-47. doi: 10.1007/s10067-013-2392-2. Epub 2013 Sep 22. Clin Rheumatol. 2014. PMID: 24057092 Free PMC article.
Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab.
Asai S, Takahashi N, Hayashi M, Hanabayashi M, Kanayama Y, Takemoto T, Yabe Y, Shioura T, Ishikawa H, Yoshioka Y, Kato T, Hirano Y, Fujibayashi T, Hattori Y, Kobayakawa T, Ando M, Kuwatsuka Y, Matsumoto T, Asai N, Sobue Y, Nishiume T, Suzuki M, Ishiguro N, Kojima T. Asai S, et al. Among authors: hattori y. Joint Bone Spine. 2020 Dec;87(6):596-602. doi: 10.1016/j.jbspin.2020.06.001. Epub 2020 Jun 10. Joint Bone Spine. 2020. PMID: 32534200 Free article.
Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study.
Asai S, Hayashi M, Hanabayashi M, Kanayama Y, Takemoto T, Yabe Y, Shioura T, Ishikawa H, Yoshioka Y, Kato T, Hirano Y, Fujibayashi T, Hattori Y, Kobayakawa T, Ando M, Kuwatsuka Y, Takahashi N, Matsumoto T, Asai N, Sobue Y, Nishiume T, Suzuki M, Ishiguro N, Kojima T. Asai S, et al. Among authors: hattori y. Mod Rheumatol. 2020 May;30(3):434-441. doi: 10.1080/14397595.2019.1641934. Epub 2019 Aug 7. Mod Rheumatol. 2020. PMID: 31390271 Free article. Clinical Trial.
Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study.
Hattori Y, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Terabe K, Yabe Y, Miyake H, Kato T, Takagi H, Hayashi M, Ito T, Kanayama Y, Oguchi T, Takahashi N, Ishikawa H, Funahashi K, Ishiguro N. Hattori Y, et al. J Rheumatol. 2016 Aug;43(8):1475-9. doi: 10.3899/jrheum.151006. Epub 2016 Jun 15. J Rheumatol. 2016. PMID: 27307531
High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab.
Hattori Y, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Oguchi T, Kanayama Y, Miyake H, Kato T, Takagi H, Hayashi M, Ito T, Shioura T, Takahashi N, Ishikawa H, Funahashi K, Ishiguro N. Hattori Y, et al. Mod Rheumatol. 2018 Jan;28(1):119-125. doi: 10.1080/14397595.2017.1317320. Epub 2017 May 2. Mod Rheumatol. 2018. PMID: 28463029
2,208 results